Streetbeat News

Price Targets

HWM

Keybanc analyst Philip Gibbs has maintained an Overweight rating on Howmet Aerospace (NYSE:HWM) and increased the price target from $52 to $60, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 12:11 pm

AGYS

Needham analyst Mayank Tandon reaffirmed a Buy rating on Agilysys (NASDAQ:AGYS) and increased the price target from $92 to $100, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 12:06 pm

GFS

Analysts have varying opinions on GLOBALFOUNDRIES (NASDAQ:GFS), with recent ratings ranging from bullish to bearish. Over the last quarter, there were 4 somewhat bullish and 1 indifferent rating. The average 12-month price target is now $68.6, down from $75.00, with a high estimate of $75.00 and a low of $65.00. Analysts from firms like Cantor Fitzgerald, B of A Securities, Morgan Stanley, JP Morgan, and Susquehanna have adjusted their price targets and ratings, reflecting changes in market conditions and company performance. GLOBALFOUNDRIES, a semiconductor manufacturer, faces challenges with a -10.7% revenue decline, below-average net margin, ROE, and ROA, but has a conservative debt-to-equity ratio of 0.25.

Portfolio Pulse from Benzinga Insights

January 23, 2024 | 12:01 pm

PWSC

PowerSchool Holdings (NYSE:PWSC) has been rated by 4 analysts in the last three months, with 3 somewhat bullish and 1 indifferent rating. The average 12-month price target is $27.5, up 3.77% from the previous $26.50. Analysts from Piper Sandler, UBS, RBC Capital, and Cantor Fitzgerald have provided recent evaluations, with price targets ranging from $25 to $30. PowerSchool Holdings is a cloud-based software provider for K-12 education, with a market cap below industry average, revenue growth of 12.15%, and strong profitability indicators like net margin, ROE, and ROA. Its debt-to-equity ratio is 0.66, indicating a sound financial structure.

Portfolio Pulse from Benzinga Insights

January 23, 2024 | 12:00 pm

TEVA

Teva Pharmaceutical Indus (NYSE:TEVA) received mixed analyst ratings over the last quarter, with 3 bullish and 1 indifferent rating. The average 12-month price target is $13.0, up from the previous $9.67, with a high estimate of $14.00 and a low of $12.00. Analysts from Jefferies, Piper Sandler, HSBC, and UBS have adjusted their price targets and ratings, reflecting a positive outlook on the company's performance. Despite this, Teva's financial indicators such as market capitalization, revenue growth, net margin, ROE, ROA, and debt management show mixed results compared to industry averages.

Portfolio Pulse from Benzinga Insights

January 23, 2024 | 12:00 pm

CPE

Callon Petroleum (NYSE:CPE) has received mixed analyst ratings over the past three months, with 1 bullish, 1 somewhat bullish, and 3 indifferent. The average 12-month price target for CPE has been lowered to $39.6, a 16.19% decrease from the previous target of $47.25. Analysts from Stifel, Mizuho, Morgan Stanley, and RBC Capital have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. Callon Petroleum operates in the oil and natural gas sector, with a focus on the Permian Basin. The company's financial performance shows challenges in revenue growth, profitability, and asset utilization, but a sound debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 23, 2024 | 12:00 pm

BNTX

BioNTech (NASDAQ:BNTX) has received mixed analyst ratings over the past three months, with 5 analysts offering diverse perspectives. The average 12-month price target is now $116.6, down from $132.25, with a high estimate of $133.00 and a low of $99.00. Analysts from firms including HC Wainwright & Co., JP Morgan, and Morgan Stanley have adjusted their ratings and price targets, reflecting changes in market dynamics and company performance. BioNTech's financial performance shows a significant revenue decline of -74.13% over a 3-month period, but strong net margin and ROE/ROA figures. The company's debt-to-equity ratio is low at 0.01, indicating a conservative debt management approach.

Portfolio Pulse from Benzinga Insights

January 23, 2024 | 12:00 pm

ALC

Bernstein analyst Susannah Ludwig has initiated coverage on Alcon (NYSE:ALC) with an Outperform rating and set a price target of $94.4 for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 11:53 am

NVS

Morgan Stanley analyst Mark Purcell has initiated coverage on Novartis with an Equal-Weight rating and set a price target of $114. The initiation of coverage is a neutral stance and the price target suggests a view on the stock's future performance.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 11:49 am

NARI

Needham analyst Mike Matson has initiated coverage on Inari Medical (NASDAQ:NARI) with a Buy rating and set a price target of $72.

Portfolio Pulse from Benzinga Newsdesk

January 23, 2024 | 11:48 am